Milagyn (clindamycin) vaginal suppositories №3


Treatment of bacterial vaginosis (previous names – hemophilic vaginitis, gardnerellosis vaginitis, nonspecific vaginitis, corynebacterial vaginitis or anaerobic vaginosis).



Milagyn composition
active substance: clindamycin;
1 suppository contains 100 mg of clindamycin phosphate in terms of clindamycin;
excipient: lipophilic base

Dosage form
Vaginal suppositories.

Pharmacological properties
The active substance of the drug Milagyn, clindamycin belongs to the group of lincosamides. Inhibits protein synthesis in the microbial cell by interacting with 50S ribosome subunits. With topical intravaginal administration of clindamycin, phosphate is hydrolyzed to clindamycin, which exhibits antibacterial activity. Clindamycin is active in vitro against the following registered strains of microorganisms associated with bacterial vaginosis: Bacteroides spp., Gardnerella vaginalis, Mobiluncus spp., Mycoplasma hominis, Peptostreptococcus spp.

Treatment of bacterial vaginosis (previous names – hemophilic vaginitis, gardnerellosis vaginitis, nonspecific vaginitis, corynebacterial vaginitis or anaerobic vaginosis).

Hypersensitivity to lincomycin, clindamycin or to other components of the drug that contain solid fat. History of regional enteritis, ulcerative colitis and antibiotic-associated colitis.

There are no data on the use of the drug in pediatric practice.

Use during pregnancy or breastfeeding
Milagin is not recommended during pregnancy due to lack of research.

Method of application and dosage
One suppository intravaginally once a day at night for 3 consecutive days. Release the suppository from the contour package and insert it deep into the vagina in a supine position with the legs bent at the knees and pulled up to the chest or squatting.
Attention should be paid to official recommendations for the appropriate use of antibacterial agents.

Cases of overdose in compliance with the recommendations for the use of the drug are unknown.
Clindamycin phosphate contained in the drug and used vaginally can be absorbed in an amount sufficient to develop systemic effects.
In case of overdose, the use of general symptomatic and supportive treatment is indicated if necessary.
If the drug is taken internally, the effects associated with therapeutic concentrations of clindamycin in the blood may occur.

Side effects
These side effects occur in less than 10% of patients.

  • From the genitourinary system: vulvovaginal disorders, vulvovaginal irritations, vaginal pain, vaginal candidiasis, menstrual irregularities, vaginal discharge, dysuria, pyelonephritis, vaginitis / vaginal infections.
  • General disorders and administration site conditions: injection site pain, fever, generalized pain, localized edema, lateral abdominal pain, headache.
  • Infections and invasions: vaginal candidiasis, fungal infections.
  • From the gastrointestinal tract: nausea, vomiting, diarrhea, abdominal cramps, localized abdominal pain.
  • From the skin and mucous membranes: itching (not at the injection site), rash, itching (at the injection site).
  • From the blood and lymphatic system: temporary neutropenia (leukopenia), agranulocytosis, thrombocytopenia.
  • From the immune system: anaphylactoid reactions.
  • Hepatobiliary disorders: jaundice.
  • From the skin and subcutaneous tissues: erythema multiforme, similar to Stevens-Johnson syndrome, toxic epidermal necrolysis.
  • Infections and invasions: bacterial infections, skin candidiasis.
  • From the immune system: hypersensitivity.
  • From the endocrine system: hyperthyroidism.
  • From the nervous system: dizziness, dysgeusia.
  • From the organs of hearing and balance: vertigo.
  • Respiratory, thoracic and mediastinal disorders: upper respiratory tract infections, epistaxis.
  • From the gastrointestinal tract: constipation, bloating, flatulence, bad breath, disorders of the gastrointestinal tract, dyspepsia.
  • From the skin and subcutaneous tissue: urticaria, erythema, maculopapular rash.
  • From the musculoskeletal system and connective tissue: back pain.
  • From the kidneys and urinary system: urinary tract infections, glucosuria, proteinuria.
  • Pregnancy, postpartum and perinatal conditions: abnormal childbirth.
  • From the genitals and breast: vulvovaginitis, uterine bleeding, Trichomonas vulvovaginitis, pelvic pain, endometriosis.
  • General disorders and administration site conditions: inflammation, pain.
  • Research results: microbiological test out of the norm.

Expiration date
2 years.
Do not use the drug after the expiration date indicated on the package.

Storage conditions
Store Milagyn at a temperature not exceeding 25 ° C. Keep out of reach of children.